Cannabinoids Decrease the Th17 Inflammatory Autoimmune Phenotype

Overview

Journal J Neuroimmune Pharmacol

Specialties Allergy & Immunology
Neurology
Pharmacology

Date 2013 Jul 30

PMID 23892791

Citations 60

Authors

Ewa Kozela

Ana Juknat

Nathali Kaushansky

Neta Rimmerman

Avraham Ben-Nun

Zvi Vogel

Affiliations

Soon will be listed here.

Abstract

Cannabinoids, the Cannabis constituents, are known to possess anti-inflammatory properties but the mechanisms involved are not understood. Here we show that the main psychoactive cannabinoid, Δ-9-tetrahydrocannabinol (THC), and the main nonpsychoactive cannabinoid, cannabidiol (CBD), markedly reduce the Th17 phenotype which is known to be increased in inflammatory autoimmune pathologies such as Multiple Sclerosis. We found that reactivation by MOG35-55 of MOG35-55-specific encephalitogenic T cells (cells that induce Experimental Autoimmune Encephalitis when injected to mice) in the presence of spleen derived antigen presenting cells led to a large increase in IL-17 production and secretion. In addition, we found that the cannabinoids CBD and THC dose-dependently (at 0.1-5 μM) suppressed the production and secretion of this cytokine. Moreover, the mRNA and protein of IL-6, a key factor in Th17 induction, were also decreased. Pretreatment with CBD also resulted in increased levels of the anti-inflammatory cytokine IL-10. Interestingly, CBD and THC did not affect the levels of TNFα and IFNγ. The downregulation of IL-17 secretion by these cannabinoids does not seem to involve the CB1, CB2, PPARγ, 5-HT1A or TRPV1 receptors. In conclusion, the results show a unique cannabinoid modulation of the autoimmune cytokine milieu combining suppression of the pathogenic IL-17 and IL-6 cytokines along with boosting the expression of the anti-inflammatory cytokine IL-10.

Citing Articles

[Recommendations of the DGRh Committee on Complementary Medicine and Nutrition on the application of selected phytotherapeutic drugs and herbal medicines in rheumatology].

Keysser G, Seifert O, Frohne I, Michalsen A, Pfeil A, Reuss-Borst M Z Rheumatol. 2025; 84(2):152-163.

PMID: 39900858 PMC: 11865164. DOI: 10.1007/s00393-024-01612-w.

Revolutionizing Neuroimmunology: Unraveling Immune Dynamics and Therapeutic Innovations in CNS Disorders.

Toader C, Tataru C, Munteanu O, Covache-Busuioc R, Serban M, Ciurea A Int J Mol Sci. 2025; 25(24.

PMID: 39769374 PMC: 11728275. DOI: 10.3390/ijms252413614.

Cannabidiol Alleviates Imiquimod-Induced Psoriasis by Inhibiting JAK2-STAT3 in a Mouse Model.

Kim M, Lee J, Kim S, Bang C Biomedicines. 2024; 12(9).

PMID: 39335596 PMC: 11428822. DOI: 10.3390/biomedicines12092084.

Cannabinoids' Role in Modulating Central and Peripheral Immunity in Neurodegenerative Diseases.

Sharon N, Yarmolinsky L, Khalfin B, Fleisher-Berkovich S, Ben-Shabat S Int J Mol Sci. 2024; 25(12).

PMID: 38928109 PMC: 11204381. DOI: 10.3390/ijms25126402.

Polarization of HIV-1- and CMV-Specific IL-17-Producing T Cells among People with HIV under Antiretroviral Therapy with Cannabis and/or Cocaine Usage.

Castro F, Guilarde A, Souza L, Guimaraes R, Pereira A, Romao P Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675425 PMC: 11054529. DOI: 10.3390/ph17040465.

References

Juknat A, Pietr M, Kozela E, Rimmerman N, Levy R, Gao F . Microarray and pathway analysis reveal distinct mechanisms underlying cannabinoid-mediated modulation of LPS-induced activation of BV-2 microglial cells. PLoS One. 2013; 8(4):e61462. PMC: 3634783. DOI: 10.1371/journal.pone.0061462. View

Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M . Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007; 13(10):1173-5. PMC: 5114125. DOI: 10.1038/nm1651. View

Mustafa A, Gillmeister L, Hernandez W, Larsen C, Witonsky S, Holladay S . Viability and function in lymphocytes cultured from the horse, chicken, and mouse: effects of different leukocyte enrichment techniques. J Immunoassay Immunochem. 2008; 29(4):370-89. DOI: 10.1080/15321810802329823. View

Malfait A, Gallily R, Sumariwalla P, Malik A, Andreakos E, Mechoulam R . The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 2000; 97(17):9561-6. PMC: 16904. DOI: 10.1073/pnas.160105897. View

Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S . IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol. 2006; 177(1):566-73. DOI: 10.4049/jimmunol.177.1.566. View

Zhang L, Yuan S, Cheng G, Guo B . Type I IFN promotes IL-10 production from T cells to suppress Th17 cells and Th17-associated autoimmune inflammation. PLoS One. 2011; 6(12):e28432. PMC: 3232207. DOI: 10.1371/journal.pone.0028432. View

Tanasescu R, Constantinescu C . Cannabinoids and the immune system: an overview. Immunobiology. 2010; 215(8):588-97. DOI: 10.1016/j.imbio.2009.12.005. View

Stern J, Keskin D, Zhang H, Lv H, Kato Z, Strominger J . Amino acid copolymer-specific IL-10-secreting regulatory T cells that ameliorate autoimmune diseases in mice. Proc Natl Acad Sci U S A. 2008; 105(13):5172-6. PMC: 2278190. DOI: 10.1073/pnas.0712131105. View

Pertwee R . Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci. 2005; 76(12):1307-24. DOI: 10.1016/j.lfs.2004.10.025. View

10.

Rimmerman N, Juknat A, Kozela E, Levy R, Bradshaw H, Vogel Z . The non-psychoactive plant cannabinoid, cannabidiol affects cholesterol metabolism-related genes in microglial cells. Cell Mol Neurobiol. 2011; 31(6):921-30. PMC: 11498456. DOI: 10.1007/s10571-011-9692-3. View

11.

Veldhoen M, Hocking R, Atkins C, Locksley R, Stockinger B . TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006; 24(2):179-89. DOI: 10.1016/j.immuni.2006.01.001. View

12.

Maresz K, Pryce G, Ponomarev E, Marsicano G, Croxford J, Shriver L . Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med. 2007; 13(4):492-7. DOI: 10.1038/nm1561. View

13.

Puffenbarger R, Boothe A, Cabral G . Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia. 1999; 29(1):58-69. View

14.

Ahern G . 5-HT and the immune system. Curr Opin Pharmacol. 2011; 11(1):29-33. PMC: 3144148. DOI: 10.1016/j.coph.2011.02.004. View

15.

Tuohy V, Yu M, Yin L, Mathisen P, Johnson J, Kawczak J . Modulation of the IL-10/IL-12 cytokine circuit by interferon-beta inhibits the development of epitope spreading and disease progression in murine autoimmune encephalomyelitis. J Neuroimmunol. 2000; 111(1-2):55-63. DOI: 10.1016/s0165-5728(00)00384-2. View

16.

Matusevicius D, Kivisakk P, He B, Kostulas N, Ozenci V, Fredrikson S . Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler. 1999; 5(2):101-4. DOI: 10.1177/135245859900500206. View

17.

Benito C, Romero J, Tolon R, Clemente D, Docagne F, Hillard C . Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci. 2007; 27(9):2396-402. PMC: 6673484. DOI: 10.1523/JNEUROSCI.4814-06.2007. View

18.

Kozela E, Lev N, Kaushansky N, Eilam R, Rimmerman N, Levy R . Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. Br J Pharmacol. 2011; 163(7):1507-19. PMC: 3165959. DOI: 10.1111/j.1476-5381.2011.01379.x. View

19.

Petereit H, Richter N, Pukrop R, Bamborschke S . Interferon gamma production in blood lymphocytes correlates with disability score in multiple sclerosis patients. Mult Scler. 2000; 6(1):19-23. DOI: 10.1177/135245850000600105. View

20.

Izzo A, Borrelli F, Capasso R, Di Marzo V, Mechoulam R . Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009; 30(10):515-27. DOI: 10.1016/j.tips.2009.07.006. View